

A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD

NCT06321198

Status	RECRUITING
Phase	Not Applicable
Sponsor	Anhui Provincial Hospital
Enrollment	12 participants

Key Eligibility Criteria

Inclusion (1)

- Subjects who understand and voluntarily sign the Informed Consent Form(ICF); 2.4-70 years; 3.Subjects with SR-aGVHD; 4.ECOGd2; 5.Subjects with II to IV grades of steroid hormone resistance;

Exclusion (17)

- Accepted systemic or local treatment of mesenchymal stem cells;
- Have severe allergy to blood products or have allergy history of heterologous protein;
- Expected survival period within 3 months;
- Alanine transaminase(ALT)or Aspartate aminotransferase(AST) $>2 \times$ upper limit of normal(ULN);Creatinine clearance rated 30ml/min or Blood Urea Nitrogen(BUN) $>2 \times$ upper limit of normal(ULN), International Normalized Ratio (INR) $>1.5 \times$ upper limit of normal(ULN);
- Have severe hepatic veno-occlusive disease(HVOD);
- ... and 12 more (see full listing online)

Locations (1 total)

Anhui Provincial Hospital, Hefei, Anhui, China